Search the site

Research

Participation in population-based case-control studies: Does the observed decline vary by socio-economic status?

An Australian study of childhood leukaemia (Aus-ALL) previously reported that control participation was positively associated with socio-economic status...

People

Associate Professor Laurence Cheung

Co-Head, Leukaemia Translational Research

News & Events

Brain Cancer Awareness Month Q&A: Dr Hetal Dholaria’s vital work for WA Kids

Each year in Australia, around 120 children are diagnosed with brain cancer, the leading cause of cancer-related death in young people.

News & Events

The Kids Research Institute Australia researchers share in State Government science grants

Four The Kids Research Institute Australia researchers are among those who have received funding in the WA State Government's Merit Award Program announced today.

News & Events

New drug hope for babies with leukaemia

Researchers at The Kids Research Institute Australia have discovered a new drug combination that could help improve survival rates for babies with leukaemia.

News & Events

A cell change that drives leukaemia

It is now known that the HOX11 gene is permanently activated in the leukaemia cells and it drives the disease.

News & Events

WA families to help find triggers for childhood leukaemia

West Australian families are being asked to play a vital role in a major new national study to unravel the causes of childhood leukaemia.

News & Events

Pioneering paediatric oncologist receives top cancer research award

Associate Professor Rishi Kotecha, Co-Head of Leukaemia Translational Research at The Kids Research Institute Australia Cancer Centre and Consultant Paediatric Oncologist at Perth Children's Hospital, has been named Cancer Council WA’s 2024 Cancer Researcher of the Year.

Research

Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade

Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4, programmed cell death protein/ligand 1 are approved for treatment of multiple cancer types.

Research

Propofol, Anesthesia, and Neurocognitive Outcomes in Patients with Pediatric Leukemia: Are We Missing the Forest for the Trees?

Britta Regli-von Ungern-Sternberg AM FAHMS MD, PhD, DEAA, FANZA Chair of Paediatric anaesthesia, University of Western Australia; Consultant